Portal de Periódicos da CAPES

Transplant-Free Survival and Interventions at 6 Years in the SVR Trial

2018; Lippincott Williams & Wilkins; Volume: 137; Issue: 21 Linguagem: Inglês

10.1161/circulationaha.117.029375

1524-4539

Jane W. Newburger, Lynn A. Sleeper, J. William Gaynor, Danielle Hollenbeck-Pringle, Peter C. Frommelt, Jennifer S. Li, William T. Mahle, Ismée A. Williams, Andrew M. Atz, Kristin M. Burns, Shan Chen, James F. Cnota, Carolyn Dunbar‐Masterson, Nancy S. Ghanayem, Caren S. Goldberg, Jeffrey P. Jacobs, Alan B. Lewis, Seema Mital, Christian Pizarro, Aaron Eckhauser, Paul C. Stark, Richard G. Ohye,

Coronary Artery Anomalies

Background: In the SVR trial (Single Ventricle Reconstruction), 1-year transplant-free survival was better for the Norwood procedure with right ventricle-to-pulmonary artery shunt (RVPAS) compared with a modified Blalock–Taussig shunt in patients with hypoplastic left heart and related syndromes. At 6 years, we compared transplant-free survival and other outcomes between the groups. Methods: Medical history was collected annually using medical record review, telephone interviews, and the death index. The cohort included 549 patients randomized and treated in the SVR trial. Results: Transplant-free survival for the RVPAS versus modified Blalock–Taussig shunt groups did not differ at 6 years (64% versus 59%, P =0.25) or with all available follow-up of 7.1±1.6 years (log-rank P =0.13). The RVPAS versus modified Blalock–Taussig shunt treatment effect had nonproportional hazards ( P =0.009); the hazard ratio (HR) for death or transplant favored the RVPAS before stage II surgery (HR, 0.66; 95% confidence interval, 0.48–0.92). The effect of shunt type on death or transplant was not statistically significant between stage II to Fontan surgery (HR, 1.36; 95% confidence interval, 0.86–2.17; P =0.17) or after the Fontan procedure (HR, 0.76; 95% confidence interval, 0.33–1.74; P =0.52). By 6 years, patients with RVPAS had a higher incidence of catheter interventions (0.38 versus 0.23/patient-year, P <0.001), primarily because of more interventions between the stage II and Fontan procedures (HR, 1.72; 95% confidence interval, 1.00–3.03). Complications did not differ by shunt type; by 6 years, 1 in 5 patients had had a thrombotic event, and 1 in 6 had had seizures. Conclusions: By 6 years, the hazards of death or transplant and catheter interventions were not different between the RVPAS versus modified Blalock–Taussig shunt groups. Children assigned to the RVPAS group had 5% higher transplant-free survival, but the difference did not reach statistical significance, and they required more catheter interventions. Both treatment groups have accrued important complications. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00115934.